<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211948</url>
  </required_header>
  <id_info>
    <org_study_id>HBP-RWR-001</org_study_id>
    <nct_id>NCT04211948</nct_id>
  </id_info>
  <brief_title>Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer</brief_title>
  <official_title>Prospective Cohort Study Comparing Robotic and Open Surgery for Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether robotic surgery has limitations in terms of
      patient age, tumor size, location, and vascular relationship when compared to open surgery
      for pancreatic cancer. Whether robotic surgery has advantages over intraoperative bleeding,
      operative time, postoperative complications (bleeding, infection, pancreatic fistula) and
      postoperative hospital stays compared to open surgery.And the differences in lymph nodes
      harvest and postoperative survival between two groups.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year overall survival rate</measure>
    <time_frame>1 year post-operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>3 years overall survival rate</measure>
    <time_frame>3 years post-operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>Within 90 days or before discharge</time_frame>
    <description>pancreatic fistula, bile leakage, hemorrhage, DGE, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1, 3years disease free survival rate</measure>
    <time_frame>1,3years post-operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Minimally Invasive Surgery</condition>
  <arm_group>
    <arm_group_label>robotic pancreatectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>robotic pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>robotic surgery</intervention_name>
    <description>Pancreatectomy with robotic assisted system</description>
    <arm_group_label>robotic pancreatectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open surgery</intervention_name>
    <description>Traditional open pancreatectomy</description>
    <arm_group_label>open surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed pancreatic ductal adenocarcinoma

          -  Patients and their families volunteered to test and signed informed consent.

        Exclusion Criteria:

          -  Preoperative exclusion:

               1. Patients with metastasis (M1)

               2. Patients with tumor recurrence

               3. Patients with artery and/or vein invasion and can't perform radical resection and
                  reconstruction

               4. Patients with poor cardiopulmonary function cannot tolerate surgery;

               5. receive neoadjuvant radiotherapy and chemotherapy before surgery;

               6. The patient or family member refuses to join the group;

               7. Pregnant patients

          -  Intraoperative exclusion:

               1. Intraoperative exploration of metastases in other parts besides the primary
                  lesion

               2. Other organs malignant tumors metastasize to the pancreas

          -  Postoperative exclusion:

               1. pathology confirmed non-pancreatic ductal adenocarcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Qin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Kai Qin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Robotic assisted surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

